Key result
SGLT-2 inhibitors significantly decreased heart failure hospitalization compared to placebo or other anti-diabetes drugs in patients with type 2 diabetes (OR 0.66; p=0.000).
Why the study?
Heart failure in T2DM increases mortality and most antidiabetic drugs have not reduced heart failure hospitalizations, prompting a meta-analysis on the effect of SGLT-2Is on hHF.
Do SGLT-2 inhibitors reduce hospitalization due to heart failure in patients with type 2 diabetes mellitus?
Population
15,70,661 patients with T2DM (including 34,322 in RCTs and 15,36,339 in observational studies)
Comparison
SGLT-2Is vs placebo or other anti-diabetes drugs
Design
Systematic review and meta-analysis of RCTs and observational studies
Follow-up
≥24 weeks
Authors
Loading...
Supports SGLT2 inhibitor use in T2DM to reduce HF hospitalization; confirms benefit across trials.
Meta-Analysis (n=1,570,661)
Do SGLT-2 inhibitors reduce hospitalization due to heart failure in patients with type 2 diabetes mellitus?
Odds Ratio: 0.66
p-value: p=0.000
SGLT-2 inhibitors significantly reduce the risk of heart failure hospitalization in patients with type 2 diabetes mellitus, including those with established heart failure.
Singh et al. (2019) conducted a meta-analysis in Type 2 diabetes mellitus (n=1,570,661). Sodium-glucose linked co-transporter 2 inhibitors (SGLT-2Is) vs. Placebo or other anti-diabetes drugs was evaluated on Hospitalization due to heart failure (hHF) (OR 0.66, p=0.000). SGLT-2 inhibitors significantly decreased heart failure hospitalization compared to placebo or other anti-diabetes drugs in patients with type 2 diabetes (OR 0.66; p=0.000).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: